Sexual Health and Prevention

This page provides verified, factual information on sexual health risks, testing options, and prevention tools relevant to adults who are sexually active with multiple partners. It is for education only and is not a substitute for professional medical advice, diagnosis, or treatment.

If you believe you have been exposed to an STI, have symptoms (discharge, sores, pain with urination, rash, etc.), or need personalized guidance, see a licensed clinician promptly. Do not post photos of symptoms, test results, or questions like “do I have something” or “what are my chances from this specific encounter.” This wiki and the subreddit are not medical clinics.

Important reminder: HEM_NSFW does not allow medical advice, symptom posts, risk-by-encounter speculation, or coordination of care. Use this page to understand general concepts, then consult a qualified healthcare provider for your individual situation.

• General education and questions about prevention methods and testing schedules
• Encouraging regular, site-specific screening
• Neutral discussion of evidence-based tools such as PrEP, PEP, and DoxyPEP
• Sharing links to official public health resources (CDC, WHO, local health departments)

• “Do I have an STI?” or “what are my chances from this encounter” posts or comments
• Sharing personal test results, medical images, or photos of symptoms
• Speculating about another person's health status
• Requests for risk assessments or “is this safe” evaluations in comments or private messages

Violations are removed under subreddit rules. The goal is to keep discussions educational while protecting privacy and avoiding misinformation.

The table below shows approximate average per-act transmission risk for a single exposure when no protection (condoms, PrEP, or other barriers) is used and the partner has the infection. HIV numbers are per-act probabilities drawn from CDC syntheses. Bacterial and skin-to-skin risks are shown as relative categories because they vary by anatomic site, bacterial/viral load, and other factors.

Key points on risk

• Receptive anal sex carries the highest per-act HIV risk among common activities.
• Oral sex is lower risk for HIV but can transmit gonorrhea, chlamydia, syphilis, and herpes.
• Condoms substantially lower risk for fluid-borne infections (HIV, gonorrhea, chlamydia) when used correctly and consistently.
• Skin-to-skin infections (HPV, herpes) can transmit even when condoms are used because they spread by contact with affected skin.
• Many gonorrhea and chlamydia infections in the throat or rectum are asymptomatic; testing only urine misses these sites.
• Actual risk varies. For HIV, a partner with undetectable viral load on effective treatment has effectively zero risk of sexual transmission (Undetectable = Untransmittable). Bacterial load, presence of other STIs, circumcision status, and other factors also influence transmission probability.
• If you are sexually active with multiple partners, regular testing every 3 to 6 months is strongly recommended by public health authorities.

Sources

• CDC HIV Risk Reduction Tool and per-act transmission syntheses (Patel et al. and subsequent updates). CDC STI surveillance and clinical guidance for relative risks by activity and site.

Several evidence-based tools can meaningfully reduce risk when used correctly and in combination with regular testing and open communication with partners and clinicians.

PrEP is highly effective at preventing HIV when taken as prescribed. It does not protect against other STIs.

Current options (as of 2026)

Daily oral PrEP:

• Tenofovir disoproxil fumarate/emtricitabine (TDF/FTC, brand Truvada) or tenofovir alafenamide/emtricitabine (F/TAF, brand Descovy). Taken as one pill daily.

Injectable cabotegravir (Apretude):

• Long-acting intramuscular injection given every 2 months after an optional oral lead-in and two initiation doses one month apart.

Injectable lenacapavir (Yeztugo):

• Newer long-acting option (approved 2025). Starts with oral tablets plus two subcutaneous injections on day 1, one more oral dose on day 2, then subcutaneous injections every 6 months. Highly convenient for those who prefer infrequent dosing.

Effectiveness

• All approved PrEP options are approximately 99% effective at preventing sexual acquisition of HIV when used as directed. Injectable options remove daily pill adherence concerns.

Access and considerations

• Discuss options with a clinician at a sexual health clinic, primary care office, Planned Parenthood, health department, or through established telehealth PrEP services. Many programs offer free or low-cost PrEP, including patient assistance programs and manufacturer support. Injectable options require in-person visits for administration. Kidney function monitoring is more important with some oral formulations; injectables may be preferable for some people with kidney concerns.

Common side effects

Oral:

• Early nausea or stomach upset (usually resolves); rare kidney effects with long-term TDF use (labs monitor this).

Cabotegravir injectable:

• Injection-site pain, swelling, or nodules; headache; fatigue.

Lenacapavir (Yeztugo):

• Injection-site reactions (lumps, pain, hardening, swelling, itching; nodules can persist for months), headache, nausea.

Emergency HIV prevention started as soon as possible and within 72 hours after a potential exposure. A 28-day course of antiretroviral medication. Effectiveness is highest when started quickly. Available at ERs, urgent care, and sexual health clinics. Transition to PrEP afterward is often recommended if ongoing risk exists.

A single 200 mg dose of doxycycline taken within 72 hours after condomless sex can reduce incidence of chlamydia (~80-90%), syphilis (~70-80%), and gonorrhea (~50% or lower due to antibiotic resistance patterns) in certain higher-risk populations (often studied in MSM and transgender women with recent STIs or multiple partners). It is not effective for HIV prevention.

It is prescribed off-label in many areas. Discuss eligibility, benefits, and potential downsides (GI upset, sun sensitivity, possible contribution to resistance, effects on microbiome) with a clinician. It is not intended for universal or daily use.

Recommended frequency

• Every 3 to 6 months if you are sexually active with multiple partners or have higher-risk exposures.
• Immediately after a known or suspected exposure (with appropriate window-period timing).
• Before starting or restarting PrEP, and at regular intervals while on PrEP (per clinician protocol, often every 3 months).
• CDC guidance for MSM and others with increased risk supports at least annual screening, with more frequent (3-6 month) testing when risk behaviors persist or multiple partners are involved.

What to include

• HIV antigen/antibody (4th generation) test.
• Syphilis (RPR or VDRL with confirmatory testing).
• Gonorrhea and chlamydia NAAT testing at all sites of exposure: urine (urethra), throat swab (pharynx), and rectal swab. Many infections are asymptomatic at extragenital sites.
• Hepatitis B and C screening when indicated by risk or vaccination status.
• Consider herpes or HPV testing only if symptoms or specific clinical reason (routine screening not recommended for asymptomatic people).

Window periods (approximate)

• HIV 4th-gen tests are usually reliable by 18-45 days. Bacterial STIs (gonorrhea/chlamydia) are detectable within 1-2 weeks by NAAT. Syphilis varies. Retest at appropriate intervals after exposure and follow clinician advice on confirmatory testing.

At-home test kits can be convenient for privacy but may not cover all anatomic sites and often require lab confirmation for positive results. Clinic-based testing with site-specific swabs is preferred for comprehensive screening, especially after known exposures or if symptoms are present.

National and established resources

• CDC Get Tested locator: https://gettested.cdc.gov
• Planned Parenthood health centers: https://www.plannedparenthood.org/health-center
• AIDS Healthcare Foundation clinics: https://www.aidshealth.org
• Local health department directory: https://www.naccho.org/membership/lhd-directory
• HIV.gov and GetYourPrEP resources for PrEP navigation and assistance programs

At-home testing options (use with awareness of limitations)

• mylabbox, Everlywell, LetsGetChecked, and similar services. Confirm positive results and obtain site-specific testing through a clinician when needed.

Many areas have low- or no-cost options through public health clinics, federally qualified health centers (FQHCs), and PrEP assistance programs. Injectable PrEP and DoxyPEP require in-person prescribing and administration in most cases.

• Use condoms correctly and consistently for vaginal and anal sex. Consider condoms or other barriers for oral sex if concerned about specific STIs (e.g., syphilis or gonorrhea transmission to throat).
• Avoid sexual contact if visible sores, unusual discharge, or other symptoms are present.
• Wash hands and genital areas before and after encounters.
• Do not share sex toys without barriers (condoms) and thorough cleaning between partners or sites.
• Avoid shaving or aggressive hair removal immediately before encounters if it causes microtears that could increase susceptibility.
• Maintain a consistent testing schedule (every 3-6 months for those with multiple partners).
• Discuss PrEP, PEP, and DoxyPEP openly with a clinician if your activity level suggests they may be appropriate tools for you.
• Stay up to date on hepatitis vaccinations and other recommended immunizations.

These steps reduce but do not eliminate risk. Regular testing remains essential because many STIs have no symptoms.

• CDC STI Facts and Treatment Guidelines: https://www.cdc.gov/std
• CDC HIV information and Risk Reduction Tool: https://www.cdc.gov/hiv
• WHO STI fact sheets: https://www.who.int/health-topics/sexually-transmitted-infections
• HIV.gov: https://www.hiv.gov
• GetYourPrEP: https://getyourprep.org/

Always cross-check information with current CDC or WHO guidance, as recommendations evolve.

File: Sexual Health & Prevention.txt